Fundraising Fox

Effex

Acquired

Founded 2023 · 9 employees on LinkedIn · 1 known investors

Effex is a cloud-based platform for Design of Experiments (DoE), letting teams design, run, analyze, and optimize multi-factor and multi-response experiments with real-time collaboration. It serves R&D and process teams in industries including pharmaceuticals, chemicals, semiconductors, and food, offering a catalogue of OMARS designs and model-selection tools.

Also known as Effex Software

Investors · 1

Company profile

researched Aug 2026

Effex is a web-based software platform for Design of Experiments (DoE), aimed at teams that plan, execute, analyze and optimize multi-factor experiments. The product centers on an interactive catalog of experimental designs that users can compare across multiple criteria simultaneously, including trade-offs between design size and quality, together with a recommender system that proposes a design for a stated problem. Supported design types include split-plot, blocked and mixture designs as well as designs with constraints, and the catalog is described as being updated continuously with new designs.

Beyond design selection, the platform covers data collection and analysis: an API for connecting external data sources, centralized input and storage of experimental data, clustering and outlier detection, assisted correlation analysis, all-subset regression with an interactive heat map for model selection and automatic statistical model recommendations, and a multi-response optimization module using prediction profilers, contour plots, desirability functions, parallel coordinate plots and probability-of-success metrics. Collaboration features include real-time sharing and commenting, publicly shareable read-only or comment-only links, and templated one-click report export, including templates described as compliant with international standards.

The company positions the platform against both simple DoE software and the one-factor-at-a-time method, arguing that its designs detect factor interactions with fewer runs and remove manual effort in experiment management, traceability and calculation. It markets to pharmaceutical, semiconductor, chemical and food industry users.

Founding story

The methodology behind Effex originated in research at the Biostatistics group of KU Leuven, led by Prof. Peter Goos and developed by Dr. Ir. José Núñez Ares. The team built a web-based platform around this research to replace what it characterized as outdated experimental planning software.

Business model

Software-as-a-service delivered through the browser, with the company advertising usage-based payment intended to avoid unused seat licenses. Sales conversations are handled through contact and demo requests on the site.

SaaS subscription/usage-based pricing; the site advertises pricing plans and a "pay only when you use" model rather than fixed licenses.

Traction

The about page reports 10 teams using Effex, more than 150 experiments designed and presence in 5 countries. A published customer reference is Kim Schildermans, Technology Manager Chemistry in Nuclear Power Plants and Concrete at ENGIE Laborelec, who states the designs allowed a test program to be completed in half the time. The company claims the platform can save up to 40% of experimental time.

Latest developments

On 17 February 2026, Minitab, LLC announced the acquisition of the Effex solution. Minitab said it will integrate Effex into the Minitab Solution Center to combine its classical DOE options with Effex's OMARS designs, optimal design algorithms, design catalogs and AI-supported design and model recommendation, serving industries including automotive, aerospace, healthcare, pharmaceuticals, food and beverage, electronics, chemicals, semiconductors and advanced manufacturing.

Full profile — market position, technology, go-to-market, geography, history

Market position

Effex positioned itself as a modern, cloud-first alternative to established desktop DoE software, claiming to be the only platform offering its OMARS design catalog. Following the February 2026 acquisition, Minitab stated that adding Effex positions Minitab as the market leader in design of experiments offerings.

Proprietary OMARS design catalog not available in other tools, automated comparison and recommendation of designs and statistical models, browser-based real-time collaboration, and usage-based pricing without required training.

Technology

The platform is built on OMARS (Orthogonal Minimally Aliased Response Surface) designs, which combine screening and response surface methodology to provide model-based experimental plans intended to deliver more information per run, higher prediction accuracy and clearer effect estimation. Additional components include optimal design algorithms, a searchable design catalog, a design recommender, all-subset regression with automatic model recommendation, clustering and outlier detection, multi-response optimization tooling, and an API for connecting data sources. The acquiring company describes the solution as combining proprietary designs, advanced modeling, artificial intelligence and cloud-based optimization.

Go-to-market

Direct sales through the website via contact and guided demo requests, supported by educational content in a knowledge center covering topics such as Pareto analysis, OMARS and the design recommender system, plus customer testimonials.

R&D, process and quality teams in pharmaceuticals, chemicals, semiconductors and the food industry; users range from newcomers to DoE to experienced statisticians.

Geography

The company reports activity in five countries; its research origins and academic partnership are with KU Leuven in Belgium. The acquirer, Minitab, is headquartered in State College, Pennsylvania, and serves customers in more than 100 countries.

History

The company states it was founded in 2023. Its about page reports 10 teams using Effex, more than 150 experiments designed and activity in 5 countries. The leadership team includes co-founder and CEO Dewi Van De Vyver, co-founder and CSO Jose Nunez Ares, CTO Romain Slootmaekers, team lead David Barreiro, statistical expert Dr. Saif Ismail Hameed, and non-operational co-founders Prof. Peter Goos and Dr. Bart De Ketelaere. On 17 February 2026, Minitab, LLC announced it had acquired the Effex solution.

Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Claimed reduction in experimental timeJan 202640%
Countries activeJan 20265
Experiments designedJan 2026150 experiments (150+)
Founded yearJan 20232023
Teams using EffexJan 202610 teams

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Timeline · 1

launches, deals, and filings
Feb 2026
Minitab acquires Effex

Minitab, LLC announced the acquisition of the Effex design of experiments and optimization solution, which it plans to integrate into the Minitab Solution Center to combine classical DOE with Effex's proprietary OMARS designs, optimal design algorithms, design catalogs, AI-based design comparison and model recommendation, and cloud-based optimization tools.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

Research sources · 6

primary sources listed

6 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Effex do?
Effex is a cloud-based design of experiments platform built on OMARS designs, acquired by Minitab in February 2026.
Who are Effex's investors?
Effex's investors include Volta Ventures.